After decades of disuse because of its teratogenic effects, thalidomide has had a resurgence of use as a promising therapeutic agent for multiple myeloma. Its mechanism of action involves activation of the immune system, antiangiogenic effects, and inhibition of cytokines. Thalidomide does not interact with the cytochrome oxidase system. It is not significantly metabolized, but it does undergo nonenzymatic hydrolysis in plasma. The resulting products are inactive. Despite the potential adverse effects of peripheral neuropathy, constipation, deep vein thrombosis, somnolence, rash, and orthostatic hypotension, thalidomide is an effective first-line agent for multiple myeloma in combination with dexamethasone or melphalan and prednisone. It has also been studied in the palliative care of patients with cytokine-based syndromes such as anorexia-cachexia syndrome. This review describes its use in oncology, hematology, and palliative care.
Teo SKProperties of thalidomide and its analogues: implications for anticancer therapy . AAPS J. 2005;7(1):E14-E19.
2.
Corral LG, Kaplan G.Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999;58(suppl 1):1107-1113.
3.
Moreira AL, Sampaio EP, Zmuidzinas A., Frindt P., Smith KA, Kaplan G.Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993 ;177(6):1675-1680.
4.
Niwayama S., Turk BE, Liu JOPotent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides. J Med Chem. 1996 ;39(16):3044-3045.
5.
Hideshima T. , Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943-2950.
6.
Kumar S., Rajkumar SVThalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006;42(11):1612-1622.
7.
Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet. 2004;43(5):311-327.
8.
Teo SK, Scheffler MR, Kook KA, et al. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women . Biopharm Drug Dispos. 2000;21(1):33-40.
Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73(2):98-103.
11.
Harris E., Behrens J., Samson D., Rahemtulla A., Russell NH, Byrne JLUse of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol. 2003;122(1):160-161.
12.
Chiou HE, Wang TE, Wang YY, Liu HWEfficacy and safety of thalidomide in patients with hepatocellular carcinoma . World J Gastroenterol. 2006;12(43):6955-6960.
13.
Somers GFPharmacological properties of thalidomide (alphaphthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother. 1960;15:111-116.
14.
Dimopoulos MA, Eleutherakis-Papaiakovou V.Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med. 2004;117(7):508-515.
15.
Mileshkin L. , Stark R., Day B., Seymour JF, Zeldis JB, Prince HMDevelopment of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507-4514.
16.
Wulff CH, Hoyer H., Asboe-Hansen G., Brodthagen H.Development of polyneuropathy during thalidomide therapy. Br J Dermatol. 1985;112(4):475-480.
17.
Fullerton PM , O’Sullivan DJThalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry.1968;31(6):543-551.
Singhal S., Mehta J., Desikan R., et al. Antitumor Activity of Thalidomide in refractory multiple myeloma . N Engl J Med. 1999;341(21):1565-1571.
20.
Grover JK, Uppal G., Raina V.The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol. 2002;13(10):1636-1640.
21.
Palumbo A., Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2007;22(2):414-423.
22.
Rajkumar SV , Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17(4):775-779.
23.
Rajkumar SV , Blood E., Vesole D., Fonseca R., Greipp PRPhase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol.2006;24(3):431-436.
24.
Osman K., Comenzo R., Rajkumar SVDeep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344(25):1951-1952.
25.
Horne MK III , Figg WD , Arlen P., et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancerPharmacotherapy. 2003;23(3):315-318.
26.
Kaur A., Yu SS, Lee AJ, Chiao TBThalidomide-induced sinus bradycardia. Ann Pharmacother. 2003;37(7):1040-1043.
27.
Clark TE, Edom N., Larson J., Lindsey LJThalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing . Drug Saf. 2001;24(2):87-117.
28.
Ng SS, Brown M., Figg WDThalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother. 2002;56(4):194-199.
29.
Rajkumar SV, Gertz MA, Witzig TELife-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma . N Engl J Med. 2000;343(13):972-973.
30.
Hall VC, El-Azhary RA, Bouwhuis S., Rajkumar SVDermatologic side effects of thalidomide in patients with multiple myeloma . J Am Acad Dermatol. 2003;48(4):548-552.
31.
Haslett P., Tramontana J., Burroughs M., Hempstead M., Kaplan G.Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24(6):1223-1227.
32.
Wohl DA, Aweeka FT, Schmitz J., et al. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. J Infect Dis. 2002;185(9):1359-1363.
33.
Chanan-Khan A., Miller KC, Takeshita K., et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005;106(10):3348-3352.
34.
Palumbo A., Bertola A., Musto P., et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104(7):1428-1433.
35.
Mesa RA, Steensma DP, Pardanani A., et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101(7):2534-2541.
36.
Weinkove R. , Reilly JT, McMullin MF, Curtin NJ, Radia D., Harrison CNLow-dose thalidomide in myelofibrosis. Haematologica. 2008;93(7):1100-1101.
37.
Gullestad L. , Ueland T., Fjeld JG, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study . Circulation. 2005;112(22): 3408-3414.
38.
Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T., Goggin PMThalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54(4):540-545.
39.
Khan ZH, Simpson EJ, Cole AT, et al. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther. 2003;17(5):677-682.
40.
Reyes-Teran G., Sierra-Madero JG, Martinez del Cerro V., et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10(13):1501-1507.
Jacobson JM , Spritzler J., Fox L., et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis. 1999;180(1):61-67.
43.
Revuz J., Guillaume JC, Janier M., et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990;126(7):923-927.
44.
Goli V.Does thalidomide have an analgesic effect? Current status and future directions . Curr Pain Headache Rep. 2007;11(2):109-114.
45.
George A., Marziniak M., Schafers M., Toyka KV, Sommer C.Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain. 2000;88(3):267-275.
46.
Peuckmann V. , Fisch M., Bruera E.Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60(2):273-292.
47.
Silva SR, Viana PC, Lugon NV, Hoette M., Ruzany F., Lugon JRThalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron. 1994;67(3):270-273.
